Eli Lilly CEO Dave Ricks told CNBC that 700,000 seniors have started GLP-1 drugs since Medicare coverage for them began, and Lilly is capturing 7 in 10 prescriptions. Reuters reported that Lilly said 30% of new U.S. oral GLP-1 patients chose its Foundayo pill.
In its most recent quarterly report, Lilly said it held 60% of the U.S. GLP-1 market, compared with Novo Nordisk's 38%. Mounjaro and Zepbound generated about $14 billion in the recent quarter, out of Lilly's total $23 billion in revenue.
The article notes that Novo Nordisk's Wegovy pill has received more prescriptions than Foundayo so far, but launched a few months earlier.
